Seagen Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen or view top-rated stocks.

Wall Street analysts have given Seagen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Seagen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Seagen.

Seagen Inc. (NASDAQ:SGEN) issued its quarterly earnings data on Thursday, April, 29th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.08. The biotechnology company had revenue of $331.98 million for the quarter, compared to analysts' expectations of $341.39 million. Seagen had a net margin of 29.07% and a trailing twelve-month return on equity of 21.41%.
View Seagen's earnings history.

Seagen's stock was trading at $104.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SGEN stock has increased by 49.6% and is now trading at $156.38.
View which stocks have been most impacted by COVID-19.

15 brokerages have issued 12 month price objectives for Seagen's shares. Their forecasts range from $145.00 to $254.00. On average, they anticipate Seagen's share price to reach $186.36 in the next year. This suggests a possible upside of 19.2% from the stock's current price.
View analysts' price targets for Seagen or view top-rated stocks among Wall Street analysts.

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Seagen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of SGEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Seagen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (26.05%), Capital International Investors (8.62%), BlackRock Inc. (6.93%), Price T Rowe Associates Inc. MD (3.92%), Primecap Management Co. CA (2.76%) and JPMorgan Chase & Co. (2.66%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes.
View institutional ownership trends for Seagen.

SGEN stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Massachusetts Financial Services Co. MA, JPMorgan Chase & Co., Putnam Investments LLC, Price T Rowe Associates Inc. MD, Primecap Management Co. CA, Lord Abbett & CO. LLC, and Jennison Associates LLC. Company insiders that have sold Seagen company stock in the last year include Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen or view top insider-selling stocks.

SGEN stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Manning & Napier Group LLC, Point72 Asset Management L.P., UBS Asset Management Americas Inc., Renaissance Technologies LLC, Voloridge Investment Management LLC, Mirae Asset Global Investments Co. Ltd., and Franklin Resources Inc..
View insider buying and selling activity for Seagen or or view top insider-buying stocks.

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGEN stock can currently be purchased for approximately $156.38.

Seagen has a market capitalization of $28.38 billion and generates $2.18 billion in revenue each year. The biotechnology company earns $613.67 million in net income (profit) each year or $3.30 on an earnings per share basis.

Seagen employs 2,092 workers across the globe.

The following companies are subsidiares of Seagen: Cascadian Therapeutics.

Seagen was founded in 1998.

The official website for Seagen is www.seattlegenetics.com.

Seagen is headquartered at 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021.

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]